About

Kyle D. Kuvalanka has served as Aktis Oncology's Chief Financial Officer since November 2025. He was previously Chief Financial Officer and Chief Business Officer of ROME Therapeutics, and earlier served as Chief Financial Officer and Chief Operating Officer of Goldfinch Bio, as well as Chief Operating Officer and principal financial officer of Syros Pharmaceuticals and Chief Business Officer of Blueprint Medicines. He holds a BA from Wesleyan University and an MBA from The Wharton School of the University of Pennsylvania.

Roles

Aktis Oncology, Inc.
Chief Financial Officer · Current role
November 2025–present
ROME Therapeutics, Inc.
Chief Financial Officer and Chief Business Officer
November 2023 - 2025
Goldfinch Bio, Inc.
Chief Financial Officer and Chief Operating Officer
April 2020 - April 2023
Syros Pharmaceuticals
Chief Operating Officer and Principal Financial and Accounting Officer
—
Blueprint Medicines Corporation
Chief Business Officer and Principal Financial and Accounting Officer
—
Takeda Pharmaceuticals / Millennium
Vice President, Corporate Strategy, Business Development and Alliance Management
2002 - September 2013

Also at Aktis Oncology, Inc.

Related

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.